These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 5158780)

  • 1. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism.
    Mones RJ; Elizan TS; Siegel GJ
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):668-73. PubMed ID: 5158780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.
    Klawans HL; Weiner WJ
    J Neurol Neurosurg Psychiatry; 1974 Apr; 37(4):427-30. PubMed ID: 4838914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of L-dopa-induced dyskinesias in 152 cases of Parkinson's disease.
    Mones RJ; Elizan TS; Siegel GJ
    Neurology; 1970 Apr; 20(4):405-6. PubMed ID: 5535050
    [No Abstract]   [Full Text] [Related]  

  • 4. L-Dopa and Parkinsonism.
    Calne DB; Sandler M
    Nature; 1970 Apr; 226(5240):21-4. PubMed ID: 4907560
    [No Abstract]   [Full Text] [Related]  

  • 5. [Problems and therapy of L-DOPA-induced dyskinesias].
    Völler GW; Deze J; Gundlach U; Muschard F
    Nervenarzt; 1972 Nov; 43(11):584-6. PubMed ID: 4564994
    [No Abstract]   [Full Text] [Related]  

  • 6. [Abnormal movements induced by L-Dopa and dopamine metabolism disorders].
    Lhermitte F; Rosa A; Comoy E; Bohuon C
    Rev Neurol (Paris); 1973 Dec; 129(6):313-24. PubMed ID: 4794176
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa induced dyskinesias in 152 patients with Parkinson's disease.
    Mones RJ; Elizan TS; Siegel G
    Trans Am Neurol Assoc; 1970; 95():286-7. PubMed ID: 5514393
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for the use of L-dopa in the torsion dystonias.
    Barbeau A
    Neurology; 1970 Nov; 20(11):96-102. PubMed ID: 4991253
    [No Abstract]   [Full Text] [Related]  

  • 9. [The therapeutic effect of L-dopa].
    Groneberg P; Struppler A
    Naturwissenschaften; 1972 Nov; 59(11):492-6. PubMed ID: 4657650
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa in Parkinsonism and the influence of previous thalamotomy.
    Hughes RC; Polgar JG; Weightman D; Walton JN
    Br Med J; 1971 Jan; 1(5739):7-13. PubMed ID: 4923653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis.
    Chase TN; Holden EM; Brody JA
    Arch Neurol; 1973 Nov; 29(5):328-33. PubMed ID: 4743883
    [No Abstract]   [Full Text] [Related]  

  • 13. [L-dopa induced psychosis-dyskinesia complex].
    Ikeda H; Baba O; Ishino H
    No To Shinkei; 1972 Mar; 14(3):275-80. PubMed ID: 5067044
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1969 Dec; 197(1):85-100. PubMed ID: 5364658
    [No Abstract]   [Full Text] [Related]  

  • 15. Theoretical implications of the use of L-dopa in parkinsonism. A review.
    Klawans H; Ilahi MM; Shenker D
    Acta Neurol Scand; 1970; 46(4):409-41. PubMed ID: 4323341
    [No Abstract]   [Full Text] [Related]  

  • 16. L-dopa in the treatment of Parkinsonism; a preliminary appraisal.
    Stellar S; Mandell S; Waltz JM; Cooper IS
    J Neurosurg; 1970 Mar; 32(3):275-80. PubMed ID: 5416909
    [No Abstract]   [Full Text] [Related]  

  • 17. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
    Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinsonism with Laevo-dopa.
    Mawdsley C
    Br Med J; 1970 Feb; 1(5692):331-7. PubMed ID: 4906702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 20. Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
    N Engl J Med; 1971 Jun; 284(24):1382-4. PubMed ID: 5576464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.